|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM29536601X |
| 003 |
DE-627 |
| 005 |
20231225083514.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2019.03.006
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0984.xml
|
| 035 |
|
|
|a (DE-627)NLM29536601X
|
| 035 |
|
|
|a (NLM)30914280
|
| 035 |
|
|
|a (PII)S1521-6616(18)30532-1
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Gao, Zhuo
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The inhibitory receptors on NK cells and CTLs are upregulated in adult and adolescent patients with secondary hemophagocytic lymphohistiocytosis
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 13.02.2020
|
| 500 |
|
|
|a Date Revised 07.12.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2019. Published by Elsevier Inc.
|
| 520 |
|
|
|a Hemophagocytic lymphohistiocytosis (HLH) includes primary HLH (pHLH) and secondary HLH (sHLH). Mutations that cause abnormal functions in natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) are frequently identified in pHLH. However, why NK cells and CTLs exhibit abnormal functions in sHLH remains unclear. Here, we demonstrated that NK cells in sHLH exhibited a high expression of inhibitory receptor NKG2A and a low expression of activating receptor NKG2D. Besides, the expression of HLA-E on lymphocyte, the adaptor of NKG2A on NK cells, was elevated in sHLH. Moreover, CTLs in sHLH patients expressed a higher level of functional exhaustion markers PD-1, TIM-3 and LAG-3 as well as a lower secretion of IFN-γ and CD107a upon stimulation. In addition, the expression of MHC-I on lymphocytes was decreased. Taken together, our study indicates a potentially pathological mechanism of sHLH and may open up new avenues for the development of immunotherapies against sHLH
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Cytotoxic T lymphocytes
|
| 650 |
|
4 |
|a Hemophagocytic lymphohistiocytosis
|
| 650 |
|
4 |
|a Natural killer cells
|
| 650 |
|
4 |
|a Surface receptors
|
| 650 |
|
7 |
|a Antigens, CD
|2 NLM
|
| 650 |
|
7 |
|a HAVCR2 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Hepatitis A Virus Cellular Receptor 2
|2 NLM
|
| 650 |
|
7 |
|a KLRC1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a KLRK1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a NK Cell Lectin-Like Receptor Subfamily C
|2 NLM
|
| 650 |
|
7 |
|a NK Cell Lectin-Like Receptor Subfamily K
|2 NLM
|
| 650 |
|
7 |
|a PDCD1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Programmed Cell Death 1 Receptor
|2 NLM
|
| 650 |
|
7 |
|a Lymphocyte Activation Gene 3 Protein
|2 NLM
|
| 650 |
|
7 |
|a Lag3 protein, human
|2 NLM
|
| 700 |
1 |
|
|a Wang, Yini
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Jingshi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Jia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Zhao
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 202(2019) vom: 01. Mai, Seite 18-28
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:202
|g year:2019
|g day:01
|g month:05
|g pages:18-28
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2019.03.006
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 202
|j 2019
|b 01
|c 05
|h 18-28
|